Partner, Lawyer

Gino Martel

• KSH Solutions Inc., a Montreal-based consulting, engineering, and EPC/EPCM project delivery services company with extensive experience in capital intensive industries such as pulp & paper, chemicals and biorefining, as well as in, energy, water and environment sectors, in connection with the sale of its shares to AFRY Group Finland OY, a Swedish public company that provides engineering, design, digital and advisory services.
• CTI Life Sciences Fund III L.P., 3B Future Health Fund and Panacea Venture Health Care Fund II, L.P., as lead investors, in connection with (a) the €39M cross-border, multi-tranche, Series A preferred share financing round of Domain Therapeutics S.A., a Paris-based biopharmaceutical company specializing in the research and development of innovative immuno-oncology drugs, and (b) the creation and financing of a Canadian operating subsidiary.
• Baylis Medical Company Inc. and its shareholders in connection with the sale of the company’s cardiology activities to Boston Scientific Corporation for USD$1.75 billion and carve-out of its DMS business.
• DMDConnects Services Inc. in the sale of its direct and indirect interests in, and assets used in connection with the operation of, DMD Marketing Corp., a healthcare identity provider dedicated to connecting marketers to key healthcare audiences, to IQVIA Inc. (NYSE:IQVIA).
• Hypertec, un fournisseur mondial de technologies de bout en bout, en lien avec (a) la vente d'un important complexe commercial industriel à Montréal (Québec) à Equinix Canada Ltd, b) la vente de l’unité commerciale de ses activités de centres de données et de services de colocation à Vantage Data Centers, l’un des chefs de file des centres de données hyperscale au monde, (c) l’acquisition de cloud.ca Inc., et (d) l’acquisition du contrôle d'Hypertec et le financement en capital-risque par F.I.T. Ventures.
• Groupe Nexio Inc. in connection with its acquisition by NovaCap.
• Corbec Group in connection with the acquisition of a hot dip galvanizing plant in Nova Scotia.
• Canassurance Financial Corporation, a not-for-profit health insurance provider operating in Ontario and Quebec, in connection with (a) the sale of its underwriting, marketing and administration of individual life, long-term disability, long-term care, and critical illness insurance business to Blue Cross Life Insurance Company of Canada, and (b) the sale of all of the shares of SecuriGlobe Inc., a wholly-owned subsidiary of Navacord Corp.
• HIM Holdings LP and its related funds in connection with the sale of the student residence complex situated at 420 Sherbrooke Street West, Montreal, Quebec to ECV Montreal LP.
• Merck Canada Inc. in connection with the Canadian aspects of the spin-off of Merck & Co.’s women’s health, legacy products and biosimilars business, which created the new company named Organon & Co. and various subsidiaries in Canada and throughout the world.
• Corbec Group in connection with the conclusion of a joint venture for the construction and operation of a hot dip galvanizing plant in the Toronto Metropolitan.
• Biodextris Inc., as co-licensor with The Brigham and Women’s Hospital, Inc., in the negotiation of a global development and commercialization agreement with I-Mab Biopharma US Limited and Jiangsu Nhwa Pharmaceutical Co., Ltd. in relation to innovative products and processes for the treatment of neurological diseases in humans.
• Baylis Medical Company in its venture arm preferred share investment in Epineuron Technologies Inc. and in its subsequent common share financing and acquisition of control of Epineuron, a bioelectronic medical company that provides therapy to support patients with peripheral nerve regeneration.
• Klox Technologies Inc. in connection with the establishment of a joint venture company in Ireland with LEO Pharma A/S.
• sanofi-aventis Canada Inc. in connection with a swap of assets with Johnson & Johnson.
• CTI Life Sciences Fund as lead investor in connection with (a) CTI’s participation in the €130M Series C equity financing of Amolyt Pharma that was lead by Sofinnova Partners and co-lead by Intermediate Capital Group, (b) CTI’s participation with BVF Partners, Omega Funds, Cowen Healthcare Investments et al., in the $138M transaction financing of enGene Inc., a clinical-stage biotechnology company listed on NASDAQ, developing non-viral gene therapies based on its proprietary dually derivatized chitosan platform that are re-dosable, manufacturable at scale and designed to be seamlessly integrated into community clinical practices across the globe, (c) the formation and Series A multi-tranche financing with adMare BioInnovations and Domain Therapeutics of Find Therapeutics Inc. and its acquisition of the assets of Peptimimesis S.A., (d) the US$6M Series A-3 preferred share seed financing in Phenomic AI Inc., a Toronto-based company which leverages a computer vision and high content screening platform to develop therapeutic antibodies against cancer and fibrosis, (e) three separate multi-tranche private placements of $3.2M, $2.5M and $2M principal amount secured convertible debentures of Zymeworks Inc. of Vancouver, the conversion of such debentures into equity, the subsequent rounds of preferred share financings and the initial public offering of Zymeworks Inc., (f) the $10M Series A multi tranche financing of Xagenic Canada Inc. and in the subsequent $20M Series B and $15M Series B-1 multi-tranche financings and convertible debt financing of Xagenic Canada Inc. of Toronto, (g) the series C preferred share financing of Phemi Systems Corporation, (h) the $100M Series B preferred share financing of DalCor Pharmaceuticals Canada Inc. and DalCor Pharma UK Ltd., (i) the cross-border, tracking share financing of NeurAxon Inc., and (j) the US$9.5M series C multi-tranche financing of CellAegis Devices Inc., a Toronto based medical device company.
• Skyfold Investments Ltd. and its shareholders in connection with the sale of the company to dormakaba for $109 million.
• Hydro-Québec Production in connection with the acquisition of a 60% interest in the hydroelectric facility located on the Manicouagan River in Quebec from Abitibi-Consolidated Company of Canada, a subsidiary of AbitibiBowater Inc. ($615M).
• Enobia Pharma Corp in connection with the negotiation and execution of a Merger Agreement with Alexion Pharmaceuticals, Inc. whereby Enobia was acquired by Alexion for US$1.08B, and in connection with its previous $40.1M Series B financing, US$50M series C financing, US$45M Series C extension financing, US$40M common stock financing and US$20M secured debt financing - Winner of LMG Life Sciences 2013 Award - Canadian Impact Deals of the Year.
• Milgram & Company Ltd. and its shareholders in connection with the sale of the company to C.H. Robinson Worldwide, Inc. for a purchase price of approximately $62 million.
• The owners of 3 senior residence facilities located in Moncton, New Brunswick in connection with the sale thereof to Moncton Retirement Limited Partnership, indirectly controlled by Hillcore Real Estate Investments Ltd.
• Valeant Pharmaceuticals on its US$3.2B merger with Biovail, Canada’s largest publicly traded pharmaceutical company, and on its subsequent $1.5B, $1B and $650M cross-border private placements and on senior secured credit facilities. Also advised on Valeant’s acquisitions, through its Canadian subsidiary, of Dr. Renaud Inc and Renaud Skin Care Products Inc, worth $23M, and of Vital Science, Derma Glow and All Healthy Skin, worth $10.5M.
• Canadian counsel to TerSera Therapeutics LLC in connection with (a) the purchase of the commercial rights to Zoladex® in the United States and Canada from AstraZeneca UK Limited for USD$250M plus certain milestone and royalty fees and (b) the concurrent first lien and second lien financing thereof.
• Raymond Chabot Grant Thornton & Co. L.L.P. in connection with the sale of its real estate consultancy services business in the Province of Quebec to Jones Lang Lasalle Real Estate Services, Inc.